More on REGN
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $734.81 |
|
|||
| Open | $740.50 | ||||
| 52 Wk High | $592.36 | ||||
| 52 Wk Low | $325.35 | ||||
| Day High | $742.50 | ||||
| Day Low | $729.20 | ||||
| P/E | 192.97 | ||||
| EPS | $3.81 | ||||
| Volume | 614,531 | ||||
- Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)
- Regeneron Pharma (REGN) PT Raised to $930 at Jefferies
- Regeneron reports 73% response rate for ubamatamab in ovarian cancer
- Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
- Regeneron drug shows muscle preservation in GLP-1 weight loss trial
- Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
- BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
- Argus Upgrades Regeneron Pharma (REGN) to Buy, 'attractive entry point '
- Regeneron and Sanofi expand alliance with $1 Bln upfront deal
- Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
Entities mentioned with REGN
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
